secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scilex Holding Co (SCLX)
CIK:        0001820190
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0000950170-24-134767
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scilex forms JV to develop Phase 2 oral KDS2010 for obesity and Alzheimer's
---------------------------------------------------------------------------

- Scilex contributes $50M of Semnur stock for controlling stake in Scilex Bio JV; IPMC holds 40%.
- NeuroBiogen grants Scilex Bio exclusive worldwide license to KDS2010 for all indications.
- KDS2010 is a reversible MAO-B inhibitor; Phase 1 shows favorable safety; Phase 2 ongoing in obesity and Alzheimer's.
- Obesity drug market forecast ~$150B by early 2030s; Alzheimer's market >$15B by 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1820190/000095017024134767/0000950170-24-134767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1820190/000095017024134767/sclx-20241210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-134767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer